

Appl. No. 09/937,452  
Amtd. Dated February 3, 2004  
Reply to Office Action of November 5, 2003

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (currently amended) A method for the *in vitro* micropropagation and phytofortification of a phytopharmaceutical plant comprising:

a) culturing a sterile explant of said phytopharmaceutical plant on an induction medium comprising at least one plant growth regulator having cytokinin activity, to form regenerated tissue;

b) transferring said regenerated tissue to a basal medium lacking said plant growth regulator having cytokinin activity, and culturing to form plantlets; and

c) subculturing said plantlets onto a basal medium containing supplemented with at least one additive of interest, to allow uptake and accumulation of said at least one additive of interest in a bio-available form in said plantlet thereby producing said phytopharmaceutical plant that is phytofortified.

2. (previously presented) The method of claim 1, wherein after said step of culturing (step a)), and prior to said step of transferring (step b)), said regenerated tissue is placed on a basal medium and subcultured to further formation of regenerated tissue.

3. (original) The method of claim 1 wherein after said step of transferring (step b)), said plantlet is transferred to a hydroponic environment with a recycling solution containing at least one additive of interest to allow uptake and accumulation of said at least one additive of interest in a bioavailable form within said plantlet or seedling.

4. (previously presented) The method according to any one of claim 1, 2 or 3, wherein in said sub-culturing step, said at least one additive of interest is selected from boron, calcium, chloride, chromium, cobalt, copper, iron, lithium, iodine, magnesium,

Appl. No. 09/937,452  
Amtd. Dated February 3, 2004  
Reply to Office Action of November 5, 2003

manganese, molybdenum, nickel, phosphorous, potassium, selenium, silicon, sodium, sulphur, tin, vanadium and zinc.

5-6. (canceled)

7. (previously presented) The method according to claim 1, wherein said at one plant growth regulator having cytokinin activity is selected from the group consisting of thidiazuron (*N*-phenyl-*N'*-(1,2,3-thiadiazol-yl)urea), benzylaminopurine(BAP), zeatin, CPPU (*N*-(2-chloro-4-pyridyl)-*N*-(phenyl urea) and 2-*I*-P (*N*6-(2-isopentenyl) adenine).

8. (original) The method according to claim 7, wherein said at least one plant growth regulator having cytokinin activity is selected from thidiazuron (TDZ) and benzylaminopurine (BAP).

9. (previously presented) The method according to claim 8, wherein said induction medium comprises from about 0.001 to about 25  $\mu\text{mol}\cdot\text{L}^{-1}$  of said at least one plant growth regulator having cytokinin activity.

10. (original) The method according to claim 8, wherein said sterile explant is maintained on said induction medium from about 1 to about 50 days.

11. (previously presented) The method according to claim 1, wherein said explant is selected from the seed, petiole, hypocotyl, stem, cotyledon and leaf.

12. (previously presented) The method according to claim 1, wherein said phytopharmaceutical plant is St. John's wort.

13. (original) The method according to claim 12, wherein said plant growth regulator having cytokinin activity is thidiazuron.

Appl. No. 09/937,452  
Amtd. Dated February 3, 2004  
Reply to Office Action of November 5, 2003

14. (original) The method according to claim 13, wherein the induction medium comprises thiadiazuron from about 0.001 to about 25  $\mu\text{mol} \cdot \text{L}^{-1}$ .

15. (original) The method according to claim 14, wherein the induction medium comprises thiadiazuron from about 4 to about 10  $\mu\text{mol} \cdot \text{L}^{-1}$ .

16. (original) The method according to claim 12, wherein said sterile explant is maintained on said induction medium from about 1 to about 15 days.

17. (original) The method according to claim 16, wherein said sterile explant is maintained on said induction medium from about 8 to about 10 days.

18. (original) The method according to claim 12, wherein said explant is etiolated hypocotyl.

19-39. (canceled)

40. (original) The method according to claim 4, wherein said at least one additive of interest is zinc.

41. (canceled)

42. (original) The method according to claim 4, wherein said at least one additive of interest within said basal medium, is from about 0.001 to about 500  $\text{mg} \cdot \text{L}^{-1}$ .

43. (previously presented) The method according to claim 2, wherein, in said transferring step, said regenerated tissue is subcultured for about 1 to about 15 days.

44. (currently amended) A method for phytofortification of an *in vitro*-grown phytopharmaceutical plant comprising:

Appl. No. 09/937,452  
Amtd. Dated February 3, 2004  
Reply to Office Action of November 5, 2003

a) culturing a sterile seedling, explant or regenerated tissues to form a plantlet; and

b) subculturing said plantlet onto a basal medium containing lacking a plant growth regulator having cytokinin activity, said basal medium supplemented with at least one additive of interest, to allow uptake and accumulation of said at least one additive of interest in a bio-available form in said plantlet to produce a phytophortified phytopharmaceutical plant.

45. (previously presented) The method according to claim 44, wherein, in said step of culturing, said plantlets are produced either:

a) on a sterile explant of said phytopharmaceutical plant grown on an induction medium comprising at least one plant growth regulator having cytokinin activity, or

b) grown from a sterile seed, or

c) seedling in culture.

46. (previously presented) The method according to claim 45, wherein said at one plant growth regulator having cytokinin activity is selected from the group consisting of thidiazuron (*N*-phenyl-*N'*-(1,2,3-thidiazol-yl)urea), benzylaminopurine (BAP), zeatin, CPPU (*N*-(2-chloro-4pyridyl)-*N*-(phenyl urea) and 2-*i*-P (*N*6-(2-isopentenyl) adenine).

47. (currently amended) A phytopharmaceutical plant prepared by the method of claim 1 and comprising an elevated level of said additive of interest introduced in said step of subculturing (step c)), when compared to a plant grown in said basal medium in the absence of said additive of interest.

48. (currently amended) A method for the in vitro micropropagation involving de novo promoting shoot formation of non-meristematic tissue of a phytopharmaceutical plant comprising the steps of:

Appl. No. 09/937,452  
Amtd. Dated February 3, 2004  
Reply to Office Action of November 5, 2003

- a) culturing a sterile explant of said phytopharmaceutical plant on an induction medium comprising one or more plant growth regulators having cytokinin activity, to form regenerated tissue; and
- b) transferring said regenerated tissue to a basal medium lacking said plant growth regulator having cytokinin activity and culturing to form plantlets, and:

wherein said steps of culturing and transferring result in the *in vitro* micropagation involving *de novo* shoot formation of non-meristematic tissue of said phytopharmaceutical plant.

49. (new) A method for the *in vitro* micropagation and phytofortification of a phytopharmaceutical plant comprising:

- a) culturing a sterile explant of said phytopharmaceutical plant on an induction medium comprising at least one plant growth regulator having cytokinin activity, to form regenerated tissue;
- b) transferring said regenerated tissue to a basal medium and culturing to form plantlets; and
- c) subculturing said plantlets onto a basal medium containing lithium, to allow uptake and accumulation of said lithium in a bio-available form in said plantlet, said basal medium lacking said plant growth regulator having cytokinin activity.